Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients

Hypertension Research

Volumn 28, Issue 3, 2005, Pages 209-214

  Fogari, Roberto ^a,b   Derosa, Giuseppe ^a   Zoppi, Annalisa ^a   Rinaldi, Andrea ^a   Lazzari, Pierangelo ^a   Fogari, Elena ^a   Mugellini, Amedeo ^a   Preti, Paola ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Clinica Medica II   (Italy)

Author keywords

Hypertension; Insulin sensitivity; Leptin; Obesity; Valsartan

Indexed keywords

FELODIPINE; LEPTIN; PLACEBO; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; OBESITY; OPEN STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TITRIMETRY;

AGED; ANTIHYPERTENSIVE AGENTS; FELODIPINE; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; OBESITY; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 20444479426     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.209     Document Type: Article

References (56)

1. National Institute of Health: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: the Evidence Report (NIH publication 98-4083). Bethesda, National Institutes of Health, 1998, pp 7-33.
2. Visscher TL, Seidell JC: The public health impact of obesity. Annu Rev Public Health 2001; 22: 355-375.
3. McLellan F: Obesity rising to alarming levels around the world. Lancet 2002; 359: 1412.
4. Kenchaiah S, Evans JC, Levy D, et al: Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
5. Eckel RH, Krauss RM, for the AHA Nutrition Committee: American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998; 97: 2099-2100.
6. Grundy SM: Obesity, metabolic syndrome and coronary atherosclerosis. Circulation 2002; 105: 2696-2698.
7. Sowers JR: Obesity as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl 8A): 37S-41S.
8. Schuldner AR, Yang R, Gong DW: Resistin, obesity and insulin resistance: the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345: 1345-1346.
9. Misra A, Garg A: Leptin: its receptor and obesity. J Invest Med 1996; 44: 540-548.
10. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K: Leptin causes vasodilation in humans. Hypertens Res 2002; 25: 161-165.
11. Barba G, Russo O, Siani A, et al: Plasma leptin and blood pressure in men: graded associaton independent of body mass and fat pattern. Obes Res 2003; 11: 160-166.
12. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M: Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079.
13. Guha PK, Villareal D, Reams GP, Freeman RH: Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 2003; 10: 211-218.
14. Rahmouni K, Haynes WG: Leptin and the cardiovascular system. Recent Prog Horm Res 2004; 59: 225-244.
15. Aneja A, El-Atat F, McFarlane SI, Sowers JR: Hypertension and obesity. Recent Prog Horm Res 2004; 59: 169-205.
16. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K: Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 2003; 26: 147-152.
17. Hall JE: The kidney, hypertension and obesity. Hypertension 2003; 41: 625-633.
18. Ferrannini E, Natali A: Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 1991; 121: 1274-1282.
19. Imazu M: Hypertension and insulin disorders. Curr Hypertens Rep 2002; 6: 477-482.
20. Nishina M, Kikichi T, Yamazaki H, Kameda K Hiura M, Uchiyama M: Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children. Hypertens Res 2003; 26: 281-288.
21. Remie R, Zaagsma J: A new technique for the study of vascular presynaptic receptors in freely moving rats. Heart Circ Physiol 1986; 251: 4463-4467.
22. Hjemdahl P: Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol 1988; 63 (Suppl 1): 27-31.
23. Umeda M, Kanda T, Murakami M: Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res 2003; 26: 485-492.
24. Ficek J, Kokot F, Chudek J, Adamczak M, Ficek R, Wiecek A: Influence of antihypertensive treatment with perindopril, pindolol or felodipine on plasma leptin concentration in patients with essential hypertension. Horm Metab Res 2002; 34: 703-708.
25. Marckham A, Goa KL: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
26. Saltiel E, Gray Ellrodt A, Monk JP, Langley MS: Felodipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 1988; 36: 387-428.
27. Remie R, Zaagsma J: A new technique for the study of vascular presynaptic receptors in freely moving rats. Heart Circ Physiol 1986; 251: 4463-4467.
28. Hjemdahl P: Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol 1988; 63 (Suppl 1): 27-31.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
30. Lansang MC, Williams GH, Carrol J: Correlation between the glucose clamp technique and the Homeostasis Model Assessment in hypertension. Am J Hypertens 2001; 14: 51-53.
31. Parhami F, Tintut Y, Ballard A, et al: Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88: 954-960.
32. Oda A, Taniguchi T, Yokoyama M: Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47: 141-150.
33. Singhal A, Farooqi IS, Cole TJ, et al: Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease. Circulation 2002; 106: 1919-1924.
34. Kuwamura T, Yoshida K, Sugawara A, et al: Impact of exercise and angiotensin converting enzyme inhibition on tumor necrois factor-α and leptin in fructose-fed hypertensive rats. Hypertens Res 2002; 25: 927-938.
35. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T: Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003; 35: 826-837.
36. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Mark P, Teboul M: Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord 2000; 24 (Suppl 4): S33-S35.
37. Giacchetti G, Falcia E, Sardu, et al: Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): S142-S143.
38. Laakso M, Karjalaainen L, Lempiainen-Kuosa P: Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-396.
39. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE: The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093-1097.
40. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P: Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 1998; 46: 467-471.
41. Iimura O, Shimamoto K, Matsuda K, et al: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353-357.
42. Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE: Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity. J Hum Hypertens 1995; 9 (Suppl 5): S45-S50.
43. Leenen FH, Holliwell D: Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639-645.
44. Hjemdahl P, Wallen NH: Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18 (Suppl A): A36-A50.
45. Fogari R, Zoppi A, Corradi L, Preti P, Malamani GD, Mugellini A: Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 2000; 18: 1871-1875.
46. Grassi G, Esler M: How to assess sympathetic activity in humans. J Hypertens 1999; 17: 719-734.
47. Mancia G, Grassi G, Giannattasio C, Serravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728.
48. Palatini P: Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep 2001; 3 (Suppl 1): S3-S9.
49. Itoh K, Imai K, Masuda T, et al: Weight loss in obese subjects reduced blood pressure and the norepinephrine excretion in only hypertensive group. J Hypertens 1998; 16 (Suppl 2): S152.
50. Klein S, Coppack SW, Mohamed-Ali V, Landt M: Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996; 45: 984-987.
51. Van Harmelen V, Reynisdottiv S, Eriksson P, et al: Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913-917.
52. Considine RV, Sinha MK, Heiman MI, et al: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334; 292-295.
53. Segal KR, Landt M, Klein S: Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-991.
54. Mohamed-Ali V, Pinkney JH, Panahloo A, et al: Relationships between plasma leptin and insulin concentrations, but not insulin resistance, in non-insulin-dependent (Type 2) diabetes mellitus. Diabet Med 1997; 14: 376-380.
55. Agata J, Masuda A, Takeda M, et al: High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171-1174.
56. Itoh K, Imai K, Masuda T, et al: Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 2002; 25: 881-886.